The Ascites drugs in development market research report provides comprehensive information on the therapeutics under development for Ascites, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ascites. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ascites and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Ascites by seven companies/universities/institutes. The top development phase for Ascites is phase iii with three drugs in that stage. The Ascites pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Ascites pipeline products market are: Protgen, Ferring International Center and Simcere Pharmaceutical Group.
The key targets in the Ascites pipeline products market include Vasopressin V1a Receptor, and Serum Albumin.
The key mechanisms of action in the Ascites pipeline product include Vasopressin V1a Receptor Agonist with two drugs in Phase I. The Ascites pipeline products include four routes of administration with the top ROA being Intravenous and five key molecule types in the Ascites pipeline products market including Recombinant Protein, and Small Molecule.
Ascites overview
Ascites is a pathological condition where there is accumulation of fluid within the peritoneal cavity. It is the most common complication of cirrhosis and occurs in about 50% of patients with decompensated cirrhosis within 10 years. Mortality increases from complications such as spontaneous bacterial peritonitis and hepatorenal syndrome.
For a complete picture of Ascites’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
